(Image: Associated Press)

No­var­tis scores its lat­est FDA OK — this time for a new sick­le cell dis­ease drug picked up in a $665M deal

No­var­tis’ de­ci­sion to buy Ok­la­homa-based biotech Se­lexys 3 years ago for up to $665 mil­lion has paid off with an FDA ap­proval to­day. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.